Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil
- 1 October 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 15 (10) , 723-730
- https://doi.org/10.1097/01.fpc.0000175598.42141.59
Abstract
The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5′-TSER, 3′-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy. Patients were followed up for 19±14 months (median±SD). TS genotypes were determined from the peripheral blood mononuclear cells of 166 patients by polymerase chain reaction–polyacrylamide gel electrophoresis and restriction fragment length polymorphism methods. 5′-TSER 3R homozygotes showed significantly longer DFS (P=0.048) and OS (P=0.009). The 5′-TSER and 3′-TSUTR genotype combination groups showed a significant difference for DFS (P=0.039) and OS (P=0.029). Significantly better DFS (P=0.049) and OS (P=0.043) were observed for 6 bp/6 bp genotypes in 5′-TSER heterozygotes (n=80). Based on this, and on hazard ratios obtained by Cox regression analysis of the DFS of genotype–combinations, the patients were classified as belonging to prognostic groups A and B. The DFS and OS of these two groups showed a highly significant difference (P=0.002 and 0.001). In the multivariate Cox regression model, beside tumour location, the prognostic classification (groups A and B) proved to be an independent prognostic factor. Our data suggest that those TS genotypes and their combinations (group A: 3R/3R with any 3′-TSUTR genotype and 2R/3R with 6 bp/6 bp), which have been reported earlier as having high TS expression, predict significantly longer DFS and OS. We found that a combination of germline TS polymorphisms is an independent prognostic marker in selecting CRC patients with worse prognosis, and it may be worthwhile to examine whether these patients would benefit from an alternative therapy.Keywords
This publication has 26 references indexed in Scilit:
- Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a reviewLangenbecks Archives Of Surgery, 2004
- A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levelsPharmacogenetics, 2004
- Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2004
- Pharmacogenomics of thymidylate synthase in cancer treatmentFrontiers in Bioscience-Landmark, 2004
- Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patientsInternational Journal of Cancer, 2003
- Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic AnalysesJournal of Clinical Oncology, 2002
- Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based ChemotherapyJournal of Clinical Oncology, 2002
- Prognostic Significance of the Thymidylate Biosynthetic Enzymes in Human Colorectal TumorsOncology, 2002
- Thymidylate Synthase: A Target for Combination Therapy and Determinant of Chemotherapeutic Response in Colorectal CancerOncology, 1999
- Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.Proceedings of the National Academy of Sciences, 1991